# Alterome Therapeutics, Inc

> Alterome Therapeutics is a San Diego-based clinical-stage biopharmaceutical company building next-generation small molecule cancer drugs aimed at specific oncogenic mutations. Using its Kraken platform - a structure-guided, machine-learning approach to drug design - Alterome has advanced two precision oncology programs into the clinic: ALTA2618, an AKT1 E17K mutation-selective inhibitor, and ALTA3263, a KRAS-selective inhibitor covering roughly 90% of KRAS mutations including G12V and G12D.

- **Founded:** 2021
- **Headquarters:** San Diego, California, United States
- **Founders:** Eric Murphy (Co-Founder & CEO), Ryan Corcoran (Co-Founder)
- **Team size:** approx. 43 employees
- **Products:** ALTA2618, ALTA3263, Kraken Platform
- **Notable:** Raised $231M total across Series A and Series B by April 2024., Advanced two drug candidates to clinical trials within three years of founding., Named to Fierce Biotech's Fierce 15 list in 2025.

## Products & services

- **ALTA2618** — Clinical-stage, highly selective small molecule inhibitor of the AKT1 E17K oncogenic mutation.
- **ALTA3263** — Clinical-stage KRAS-selective inhibitor designed to cover roughly 90% of KRAS mutations including G12V and G12D.
- **Kraken Platform** — Structure-guided, machine-learning drug discovery engine that combines proprietary co-crystal data, molecular dynamics, free energy perturbation, and quantum chemistry to design alteration-specific inhibitors.

## Achievements

- Raised $231M total across Series A and Series B by April 2024.
- Advanced two drug candidates to clinical trials within three years of founding.
- Named to Fierce Biotech's Fierce 15 list in 2025.
- Recognized as Best Place to Work three consecutive years (2023-2025).
- Built a KRAS inhibitor designed to cover ~90% of KRAS mutations.

## Latest updates

- **2026-02** — Appointed Leo Faoro, MD, MBA as Chief Medical Officer to oversee clinical development of ALTA2618 and ALTA3263.
- **2025** — Named to Fierce Biotech's Fierce 15.
- **2024-04** — Closed $132M Series B led by Goldman Sachs Alternatives.

## Links

- Website: https://alterome.com
- LinkedIn: https://www.linkedin.com/company/alterome
- Twitter/X: https://twitter.com/AlteromeTx

---

Profile page: https://yespress.io/alterome-therapeutics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-29